Effectiveness of duloxetine versus other therapeutic modalities in patients with diabetic neuropathic pain: a systematic review and meta-analysis

Vista sencilla de ítem
dc.contributor.authorValenzuela Fuenzalida, Juan José
dc.contributor.authorLópez Chaparro, Michelle
dc.contributor.authorBarahona Vásquez, Marisol
dc.contributor.authorCampos Valdes, Javiera
dc.contributor.authorCordero Gonzalez, Javiera
dc.contributor.authorNova Baeza, Pablo
dc.contributor.authorOrellana-Donoso, Mathias
dc.contributor.authorSuazo Santibañez, Alejandra
dc.contributor.authorOyanedel Amaro, Gustavo
dc.contributor.authorGutiérrez Espinoza, Héctor
dc.date.accessioned2025-03-19T12:46:35Z
dc.date.available2025-03-19T12:46:35Z
dc.date.issued2024-06-05
dc.description.abstractObjectives: Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes mellitus (DM) with symptoms like intense pain and impaired quality of life. This condition has no treatment; instead, the pain is managed with various antidepressants, including duloxetine. The aim of this study is to analyze the evidence on the efficacy of duloxetine in the management of DPN. Methods: A systematic search in different databases was conducted using the keywords "diabetic neuropathy", "duloxetine therapy", "neuropathic pain", and "Diabetes Mellitus". Finally, eight studies were included in this meta-analysis. Results: All articles comparing duloxetine at different doses vs. a placebo reported significant differences in favor of duloxetine on pain scales like 24 h Average Pain Severity (standardized mean difference [SMD] = -1.06, confidence interval [CI] = -1.09 to -1.03, and p < 0.00001) and BPI Severity (SMD = -0.70, CI = -0.72 to -0.68, and p < 0.00001), among others. A total of 75% of the meta-analyses of studies comparing duloxetine at different doses showed a tendency in favor of the 120 mg/d dose. There were significant differences in favor of duloxetine when compared to routine care on the Euro Quality of Life (SMD = -0.04, CI = -0.04 to -0.03, and p < 0.00001) and SF-36 Survey (SMD = -5.86, CI = -6.28 to -5.44, and p < 0.00001) scales. There were no significant differences on the visual analog scale (VAS) when comparing duloxetine and gabapentin. Conclusions: Duloxetine appears to be effective in the management of DPN in different pain, symptom improvement, and quality of life scales.
dc.identifier.citationPharmaceuticals, Vol. 17, N°7, 856 (2024) p.1-25
dc.identifier.doihttps://doi.org/10.3390/ph17070856
dc.identifier.issne1424-8247
dc.identifier.orcidhttps://orcid.org/0000-0002-1781-062X
dc.identifier.urihttp://hdl.handle.net/20.500.12254/4062
dc.language.isoen
dc.publisherMDPI
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectDiabetic neuropathy
dc.subjectDuloxetine therapy
dc.subjectNeuropathic pain
dc.subjectType 1 diabetes mellitus
dc.subjectType 2 diabetes mellitus
dc.titleEffectiveness of duloxetine versus other therapeutic modalities in patients with diabetic neuropathic pain: a systematic review and meta-analysis
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
pharmaceuticals-17-00856-v2 (1).pdf
Tamaño:
6.59 MB
Formato:
Adobe Portable Document Format
Descripción:
Texto completo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas